QSAM Biosciences, Inc.
QSAM · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $1,099 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $549 | $275 | $274 | $0 |
| Gross Profit | $0 | -$275 | -$274 | $0 |
| % Margin | 0% | – | – | – |
| R&D Expenses | $141 | $364 | $448 | $207 |
| G&A Expenses | $339 | $795 | $790 | $859 |
| SG&A Expenses | $339 | $795 | $790 | $859 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,001,703,668 | $0 | $0 | $0 |
| Operating Expenses | $480 | $1,159 | $1,238 | $1,066 |
| Operating Income | -$480 | -$1,159 | -$1,238 | -$1,066 |
| % Margin | -43.7% | – | – | – |
| Other Income/Exp. Net | -$4 | -$5 | -$0 | -$441 |
| Pre-Tax Income | -$484 | -$1,164 | -$1,238 | -$1,507 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$484 | -$1,164 | -$1,238 | -$1,507 |
| % Margin | -44% | – | – | – |
| EPS | -0.13 | -0.36 | -0.43 | -0.9 |
| % Growth | 63.9% | 16.3% | 52.2% | – |
| EPS Diluted | -0.13 | -0.36 | -0.43 | -0.9 |
| Weighted Avg Shares Out | 3,609 | 3,452 | 2,968 | 2,331 |
| Weighted Avg Shares Out Dil | 3,609 | 3,452 | 2,968 | 2,331 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $4 | $5 | $0 | $441 |
| Depreciation & Amortization | $44 | -$40 | $122 | $36 |
| EBITDA | -$436 | -$1,159 | -$1,116 | -$1,033 |
| % Margin | -39.7% | – | – | – |